Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (4011)	4/9/1998 3:22:00 AM
From: billkirn	Read Replies (2) \| Respond to of 6136

Margie, we might be getting more insider selling to spook the stock. Any new info. on Donna,Peter,Stephenee,...... etc. Bill

To: margie who wrote (4011)	4/9/1998 2:05:00 PM
From: Steve Fancy	Respond to of 6136

Margie, looks like you may have hit this one on the head...price drop is looking like it may have been influenced by stop loss orders at 35-36. I wouldn't assume it's just daytraders. I'll bet there is many a longer term holder such as myself who have no interest in revisiting the twenties. In that I watch the market all day every day, I never use stop loss orders. Thanks again for your reassurance. Shouldn't take much good news to permanently force out some of the shorts. sf

To: margie who wrote (4011)	4/9/1998 6:56:00 PM
From: Oliver & Co	Read Replies (1) \| Respond to of 6136

"Improvement in CD4 Cell Counts Despite Persistently Detectable HIV Load" New England Journal of Medicine (04/09/98) Vol. 338, No. 15, P. 1074; Levitz, Stuart M.; Letter ÿÿÿÿ Stuart M. Levitz of the Boston Medical Center illustrates two cases of HIV-infected patients with elevated viral loads despite antiretroviral therapy and comments on options for the patients in a letter to the editor of the New England Journal of Medicine. He notes that one major goal of antiretroviral regimens is to reduce the HIV viral load in patients and that patients who fail treatment are left with few medical options due to the limited number of drugs available, cross-resistance, antagonism, and adverse effects.ÿ Levitz describes two patients who failed antiretroviral treatment of zidovudine, didanosine, stavudine, and lamivudine, either in combination or alone.ÿ Patient 1 presented in 1992 with a CD4 cell count of less than 40 cells/microliter, and Patient 2 had a CD4 cell count of less than 30 cells/microliter in 1993.ÿ In late 1996, Patient 1 was switched to a regimen consisting of nelfinavir, didanosine, lamivudine, and stavudine, while Patient 2 initiated a ritonavir, saquinavir, didanosine, and stavudine regimen early the next year.ÿ Both showed substantial increases in CD4 cell counts at the most recent assessment, with Patient 1 reporting 526 CD4 cells/microliter and Patient 2 showing 375 CD4 cells/microliter. Despite the fact that both still had elevated HIV viral loads, neither patient has had further opportunistic infections and both have returned to work or school.ÿ The findings show that CD4 cell increases can occur even in the presence of relatively high viral loads, Levitz noted, warning that the duration of the increased CD4 cell counts still needs to be determined.